Stevanato Group S P A (STVN) Stock News

Stevanato Group (NYSE: STVN) announced on October 21, 2025 a multi‑million investment to expand drug delivery system manufacturing at its Bad Oeynhausen, Germany site.

The project adds >2,500 square meters of advanced production space with an ISO 8 cleanroom, injection molding and automated assembly to support proprietary devices and contract manufacturing. Key platforms named are the Aidaptus autoinjector and Alina pen injector. The upgrade aims to strengthen European supply‑chain integration and combine glass primary packaging, analytical services, and equipment manufacturing to improve flexibility, scalability, and speed‑to‑market for pharma and biotech partners.

Stevanato Group (NYSE: STVN), a leading provider of drug containment, delivery, and diagnostic solutions, has announced its participation in two major investor conferences in September 2025:

The company will present at the 23rd Annual Morgan Stanley Global Healthcare Conference in New York City on September 9, 2025, at 7:45 a.m. ET, and at the Bank of America Global Healthcare Conference in London on September 24, 2025, at 10:45 a.m. BST.

Live webcasts will be available on the company's website, with replays accessible for approximately 90 days after each event.

Stevanato Group (NYSE:STVN) reported strong Q2 2025 financial results with revenue increasing 8% to €280.0 million. The company's high-value solutions represented 42% of total revenue, reaching €116.8 million. The Biopharmaceutical and Diagnostic Solutions (BDS) segment grew 10%, while the Engineering segment declined 2%.

Key financial metrics showed improvement with gross profit margin increasing 210 basis points to 28.1% and adjusted EBITDA margin rising 240 basis points to 23.2%. The company maintained its fiscal 2025 guidance, expecting revenue between €1.160-1.190 billion and adjusted diluted EPS of €0.50-0.54.

Stevanato Group (NYSE: STVN) has secured €200 million in financing through agreements with multiple banks to support its capital expenditure projects. The funding breakdown includes €100 million from BNL BNP Paribas, €50 million from CDP, and €50 million from Banco BPM.

The financing will support expansion projects at the company's facilities in Cisterna di Latina (Italy) and Fishers (Indiana, U.S.). The funds will be used to enhance pre-filled syringe production, set up ready-to-use (RTU) cartridge capacity, and complete device manufacturing construction, supporting the company's growing biologics programs.

Stevanato Group (NYSE: STVN), a leading provider of drug containment, drug delivery, and diagnostic solutions, has scheduled its second quarter 2025 financial results announcement for August 5, 2025, at 6:30 a.m. ET.

The company will host a conference call and webcast at 8:30 a.m. ET on the same day. Management will reference a slide presentation available on the company's Investor Relations website. Participants can pre-register for immediate access or join through various dial-in numbers provided for Italy, United Kingdom, and United States.

Stevanato Group (NYSE: STVN), a leading provider of drug containment, delivery, and diagnostic solutions, has announced its participation in three major investor conferences in May and June 2025:

• Bank of America Securities Healthcare Conference in Las Vegas - May 14, 2025, at 5:00 p.m. PT
• William Blair Growth Stock Conference in Chicago - June 4, 2025, at 1:20 p.m. CT
• Jefferies Global Healthcare Conference in New York City - June 5, 2025, at 10:30 a.m. ET

Live webcasts will be available on the company's website under the "Investors" section, with replays accessible for approximately 90 days after each event.

Stevanato Group (NYSE: STVN) reported strong Q1 2025 financial results with revenue increasing 9% to €256.6 million. The growth was primarily driven by an 11% increase in the Biopharmaceutical and Diagnostic Solutions (BDS) Segment, while the Engineering Segment saw a 4% decline. High-value solutions represented 43% of total revenue, reaching €110.3 million. The company's gross profit margin improved by 80 basis points to 27.2%, and adjusted EBITDA margin increased 100 basis points to 22.4%. For fiscal 2025, Stevanato maintains its revenue guidance of €1,160-1,190 million but updated its adjusted EBITDA guidance to €288.5-301.8 million and adjusted EPS to €0.50-0.54 to reflect tariff impacts. The company generated strong free cash flow of €29.7 million in Q1 2025, with cash and cash equivalents of €90.7 million and net debt of €300.2 million at quarter-end.

Stevanato Group (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, at 6:30 a.m. ET.

The company will host a conference call and webcast at 8:30 a.m. ET on the same day, featuring a management presentation with accompanying slides. These materials will be available on the company's Investor Relations website under the 'Financial Results' section.

Participants can access the call through pre-registration, direct dial-in numbers available for Italy, United Kingdom, and United States, or via a live webcast. A replay of the webcast will be archived for three months on the company's website.

Stevanato Group (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for pharmaceutical, biotechnology, and life sciences industries, has announced its participation in the KeyBanc Capital Markets Healthcare Forum.

The event is scheduled for March 18-19, 2025, with the company's presentation set for Tuesday, March 18, at 3:00 p.m. ET. Investors and interested parties can access the live webcast through the 'Investors' section of Stevanato's website at www.stevanatogroup.com. The presentation recording will remain available for approximately 90 days following the event.